Agios Pharmaceuticals, Inc. (AGIO)
34.13
-0.08
(-0.23%)
USD |
NASDAQ |
Sep 02, 16:00
34.30
+0.17
(+0.50%)
Pre-Market: 08:35
Agios Pharmaceuticals Cash from Investing (Quarterly) : 40.21M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.21M |
| March 31, 2026 | 141.31M |
| December 31, 2025 | 90.08M |
| September 30, 2025 | 95.56M |
| June 30, 2025 | 78.97M |
| March 31, 2025 | 112.59M |
| December 31, 2024 | -49.16M |
| September 30, 2024 | 250.79M |
| June 30, 2024 | 37.24M |
| March 31, 2024 | 124.56M |
| December 31, 2023 | 95.51M |
| September 30, 2023 | 39.34M |
| June 30, 2023 | 47.12M |
| March 31, 2023 | 57.60M |
| December 31, 2022 | 82.95M |
| September 30, 2022 | 104.07M |
| June 30, 2022 | 82.81M |
| March 31, 2022 | -26.57M |
| December 31, 2021 | -94.42M |
| September 30, 2021 | -232.73M |
| June 30, 2021 | -298.15M |
| March 31, 2021 | 1.874B |
| December 31, 2020 | 71.05M |
| September 30, 2020 | -125.90M |
| June 30, 2020 | 22.46M |
| Date | Value |
|---|---|
| March 31, 2020 | 108.14M |
| December 31, 2019 | -184.77M |
| September 30, 2019 | 80.38M |
| June 30, 2019 | 64.48M |
| March 31, 2019 | 131.35M |
| December 31, 2018 | -12.80M |
| September 30, 2018 | 2.771M |
| June 30, 2018 | -96.26M |
| March 31, 2018 | -167.53M |
| December 31, 2017 | 41.85M |
| September 30, 2017 | 66.42M |
| June 30, 2017 | -275.72M |
| March 31, 2017 | 109.55M |
| December 31, 2016 | -77.52M |
| September 30, 2016 | -62.74M |
| June 30, 2016 | 35.74M |
| March 31, 2016 | -14.83M |
| December 31, 2015 | 20.96M |
| September 30, 2015 | 30.16M |
| June 30, 2015 | 32.21M |
| March 31, 2015 | 44.99M |
| December 31, 2014 | -287.30M |
| September 30, 2014 | -15.10M |
| June 30, 2014 | -18.67M |
| March 31, 2014 | -12.26M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Biogen, Inc. | -3.839B |
| Insmed, Inc. | 24.51M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Exelixis, Inc. | 91.43M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -57.31M |
| Cash from Financing (Quarterly) | 3.149M |
| Free Cash Flow | -365.25M |
| Free Cash Flow Per Share (Quarterly) | -0.9838 |
| Free Cash Flow to Equity (Quarterly) | -53.95M |
| Free Cash Flow to Firm (Quarterly) | -58.52M |
| Free Cash Flow Yield | -18.24% |